Skip to main content
. Author manuscript; available in PMC: 2018 Nov 5.
Published in final edited form as: J Invest Dermatol. 2017 Apr 24;137(8):1663–1670. doi: 10.1016/j.jid.2017.04.008

Figure 1. CXCL9 and CXCL10 are elevated in morphea serum.

Figure 1.

(a) CXCL9 and CXCL10 are present at increased concentrations compared with control samples. (b, c) CXCL9 is increased in active morphea, decreases in inactive disease, and correlates with disease activity, but CXCL10 does not. (d) Both correlate with measures of disease damage. (e) CXCL9 concentrations correlate with CXCL10 concentrations. LoSDI, Localized Scleroderma Skin Damage Index; mLoSSI, modified Localized Scleroderma Skin Severity Index.